Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886319 | 0.93 | KDM4E (0.32) | KDM4EMAPK1HIF1A | |
| SCHEMBL14591103 | 0.83 | SIGMAR1 (0.36) | — | |
| SCHEMBL22603233 | 0.81 | — | — | |
| SCHEMBL25907861 | 0.80 | MAOA (0.32) | KDM4EMAPK1HIF1A | |
| SCHEMBL26547854 | 0.80 | KDM4E (0.30) | KDM4EMAPK1HIF1A | |
| SCHEMBL19084902 | 0.80 | KDM4E (0.30) | KDM4EMAPK1HIF1A | |
| SCHEMBL24103200 | 0.80 | KDM4E (0.52) | KDM4EMAPK1HIF1APAOXMEN1 | |
| SCHEMBL7766885 | 0.79 | KDM4E (0.40) | KDM4EMAPK1HIF1APAOXMEN1 | |
| SCHEMBL23945710 | 0.78 | KDM4E (0.33) | KDM4EMAPK1HIF1AMEN1KMT2A | |
| SCHEMBL21991783 | 0.78 | KDM4E (0.33) | KDM4EMAPK1HIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-10968168-B2 | Isocyanate production method | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-02-11 | — | — | US | disclosed |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | IDH3A, ALKBH3, CPS1 | KDM4E 77/4885MAPK1 4293/4885HIF1A 1640/4885 |
| US-10968168-B2 | Isocyanate production method | IDH3A, ALKBH3, CPS1 | KDM4E 77/4885MAPK1 4293/4885HIF1A 1640/4885 |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | KDM4E 1848/4885MAPK1 4411/4885HIF1A 3022/4885 |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | KDM4E 1848/4885MAPK1 4411/4885HIF1A 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.